CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
Research and development		$ 214,447	$ 2,351,852	$ 457,449	$ 6,077,440
General and administrative		1,253,070	1,619,543	2,781,683	3,314,618
Total operating expenses		1,467,517	3,971,395	3,239,132	9,392,058
Loss before other income (expense)		(1,467,517)	(3,971,395)	(3,239,132)	(9,392,058)
Interest income, net and other		43,084	94,087	99,409	173,977
Loss from continuing operations		(1,424,433)	(3,877,308)	(3,139,723)	(9,218,081)
Net loss		$ (1,424,433)	$ (3,877,308)	$ (3,139,723)	$ (9,218,081)
Loss per common share, basic ( in dollar per share)	[1]	$ (2.37)	$ (11.45)	$ (5.62)	$ (27.61)
Loss per common share, diluted ( in dollar per share)	[1]	$ (2.37)	$ (11.45)	$ (5.62)	$ (27.61)
Weighted average number of shares outstanding, basic (in shares)		600,417	338,638	558,518	333,894
Weighted average number of shares outstanding, diluted (in shares)		600,417	338,638	558,518	333,894

[1] Share and per share amounts have been restated to reflect the 1-for-8 reverse stock split effected in June 14, 2024 on retroactive basis for all periods presented.